Upregulation of checkpoints (PD-1, CTLA-4, and TIM-3) and their ligands (PD-L1 and PD-L2) in the TME can mediate tumor cells to escape immune surveillance by modulating T-cell activity (13, 18, 42, 43). This evidence concerns the gene HAVCR2 and neoplasm.